BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors. 2003

Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104, USA. smithab@sas.upenn.edu

The design, synthesis, and biological evaluation of a series of HIV-1 protease inhibitors [(-)-6, (-)-7, (-)-23, (+)-24] based upon the 3,5,5-trisubstituted pyrrolin-4-one scaffold is described. Use of a monopyrrolinone scaffold leads to inhibitors with improved cellular transport properties relative to the earlier inhibitors based on bispyrrolinones and their peptide counterparts. The most potent inhibitor (-)-7 displayed 13% oral bioavailability in dogs. X-ray structure analysis of the monopyrrolinone compounds cocrystallized with the wild-type HIV-1 protease provided valuable information on the interactions between the inhibitors and the HIV-1 enzyme. In each case, the inhibitors assumed similar orientations for the P2'-P1 substituents, along with an unexpected hydrogen bond of the pyrrolinone NH with Asp225. Interactions with the S2 pocket, however, were not optimal, as illustrated by the inclusion of a water molecule in two of the three inhibitor-enzyme complexes. Efforts to increase affinity by displacing the water molecule with second and third generation inhibitors did not prove successful. Lack of success with this venture is a testament to the difficulty of accurately predicting the many variables that influence and build binding affinity. Comparison of the inhibitor positions in three complexes with that of Indinavir revealed displacements of the protease backbones in the enzyme flap region, accompanied by variations in hydrogen bonding to accommodate the monopyrrolinone ring. The binding orientation of the pyrrolinone-based inhibitors may explain their sustained efficacy against mutant strains of the HIV-1 protease enzyme as compared to Indinavir.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III

Related Publications

Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors.
November 2011, Bioorganic & medicinal chemistry letters,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
January 1993, Drug design and discovery,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
August 1996, Journal of medicinal chemistry,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
May 2005, Journal of medicinal chemistry,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors.
July 2005, Bioorganic & medicinal chemistry letters,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
September 2019, Bioorganic & medicinal chemistry letters,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
October 2008, Bioorganic & medicinal chemistry letters,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
February 2019, Bioorganic & medicinal chemistry letters,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
March 2010, Bioorganic & medicinal chemistry,
Amos B Smith, and Louis-David Cantin, and Alexander Pasternak, and Lisa Guise-Zawacki, and Wenquin Yao, and Adam K Charnley, and Joseph Barbosa, and Paul A Sprengeler, and Ralph Hirschmann, and Sanjeev Munshi, and David B Olsen, and William A Schleif, and Lawrence C Kuo
Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
November 2015, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!